Multiple Myeloma: International Myeloma Foundation : ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

back

ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD
Hospital Clinico Universitario
Salamanca, Spain

	12.07.11
Be the first to comment Name Email Address URL Remember personal info? Comments (You may use HTML tags for style)	print share \| related articles

Be the first to comment